BEST UNLIMITED TURBO LONG CERTIFICATE - ELI LILLY & CO | Real-time Euronext Paris 08:08:06 25/06/2024 BST | ||
| 3.98 EUR | -3.63% |
|
| Current month | +59.46% | ||
| 1 month | +65.20% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
More news
| Date | Price | Change |
|---|---|---|
| 25/06/24 | 3.98 | -3.63% |
| 24/06/24 | 4.13 | +5.90% |
| 21/06/24 | 3.9 | -3.23% |
| 20/06/24 | 4.03 | +0.88% |
| 19/06/24 | 3.995 | +2.17% |
Real-time Euronext Paris
Last update June 25, 2024 at 08:08 am
More quotesStatic data
| Product type | Certificat Turbo |
|---|---|
| Buy / Sell | CALL |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | 
Société Générale
|
| 7A86S | |
| ISIN | DE000SU78318 |
| Date issued | 13/02/2024 |
| Strike | 683.8 $ |
| Maturity | Unlimited |
| Parity | 50 : 1 |
| Emission price | 1.54 € |
| Emission volume | N/A |
| Settlement | règlement en espèces |
| Currency | EUR |
Technical Indicators
| Highest since issue | 4.21 € |
|---|---|
| Lowest since issue | 0.95 € |
| Spread | 0.04 € |
| Spread % | 1.00% |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
890.1
USD
Average target price
860.5
USD
Spread / Average Target
-3.32%
- Stock Market
- Certificates
- 7A86S Certificat
